PAI-1 4G/5G polymorphism and plasma levels association in patients with coronary artery Disease

Arquivos Brasileiros de Cardiologia

Volumn 97, Issue 6, 2011, Pages 462-467

  Lima, Luciana Moreira ^a,b   Carvalho, Maria das Graças ^b   Neto, Cirilo Pereira Fonseca ^c   Garcia, José Carlos Faria ^c   Sousa, Marinez Oliveira ^b  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Hospital Geral Socor   (Brazil)

Author keywords

Coronary disease.references; Genetic; Plasminogen activator inhibitor 1 genetics; Polymorphism

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMATOSIS; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADULT; CORONARY ARTERY DISEASE; CORONARY STENOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 84863409588     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2011005000110     Document Type: Article

References (21)

1. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem. 2008;15(9):923-9.
2. Eriksson P, Kallin B, Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92(6):1851-5.
3. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promotor polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost. 1995;74(4):1032-4.
4. Nauck M, Wieland H, März W. Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves. Clin Chem. 1999;45(8 Pt 1):1141-7.
5. Rallidis LS, Gialeraki A, Merkouri E, Liakos G, Dagres N, Sionis D, et al. Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction. J Thromb Thrombolysis. 2010;29(4):497-502.
6. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367(9511):651-8.
7. Visanji JM, Seargent J, Tahri D, Croft SA, Makris M, Preston FE, et al. Influence of the -675 4G/5G dimorphism of the plasminogen activador inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. Brit J Haematol. 2000;110(1):135-8.
8. Anvari A, Schuster E, Gottsauner-Wolf M, Wojta J, Huber K. PAI-1 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res. 2001;103(2):103-7.
9. Koch W, Schrempf M, Erl A, Mueller JC, Hoppmann P, Schömig A, et al. 4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. Thromb Haemost. 2010;103(6):1170-80.
10. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89(9):993-7.
11. Naran HN, Chetty N, Crowther NJ. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis. 2008;196(1):155-63.
12. Gardemann A, Lohre J, Katz N, Tillmanns, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost. 1999;82(3):1121-6.
13. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, et al. The 4G/5G sequence polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998;79(5):975-9.
14. Fu L, Jin H, Song K, Zhang C, Shen J, Huang Y. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Chin Med J. 2001;114(3):266-9.
15. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J. 2003;116(11):1707-10.
16. Mikkelsson J, Perola M, Wartiovaara U, Peltonen L, Palotie A, Penttila A, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb Haemost. 2000;84(1):78-82.
17. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1999;34(6):1778-83.
18. Mulligan-Kehoe MJ, Schwartz GN. The functions of plasminogen activator inhibitor-1: Do we have all the pieces of PAI? Thromb Res. 2006;117(5):483-6.
19. Sugano T, Tsuji H, Masuda H, Nakagawa K, Nishimura H, Kasahara T, et al. Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population. Blood Coagul Fibrinolysis. 1998;9(2):201-4.
20. Pieters M, de Lange Z, Hoekstra T, Ellis SM, Kruger A. Triglyceride concentration and waist circumference influence alcohol-related plasminogen activator inhibitor-1 activity increase in black South Africans. Blood Coagul Fibrinolysis. 2010;21(8):736-43.
21. Hong Y, Pedersen NL, Egberg N, de Faire U. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. Arterioscler Thromb Vasc Biol. 1997;17(11):2776-82.